Dr. Zain on Investigational Approaches in Peripheral T-Cell Lymphoma

Video

In Partnership With:

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

Immunotherapy is one of many areas of interest in PTCL, says Zain. Although CAR T-cell therapy has failed to show great responses in PTCL, trials are planned to investigate the use of bispecific T-cell engagers (BiTEs) as well as antibody-drug conjugates (ADCs). The potential for ADCs in the field was demonstrated with brentuximab vedotin (Adcetris), an anti-CD30 ADC. Researchers just completed a trial evaluating an anti-CD25 ADC. CD25 may become a viable target for ADCs and BiTEs alike, says Zain.

Another exciting drug that has garnered a lot of interest as a single agent and in combination in PTCL is mogamulizumab (Poteligeo). In 2018, the agent received regulatory approval for use in patients with cutaneous T-cell lymphoma (CTCL) and Sezary syndrome. The agent targets CCR4, which is a marker of T-cell lymphomas. Moreover, the chemokine receptor is highly expressed in adult T-cell leukemia/lymphoma which is a subtype of T-cell lymphomas and CTCL.

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Phillip J. Koo, MD